CANCERS BRONCHIQUES A PETITES CELLULES

CANCERS BRONCHIQUES A PETITES CELLULES
CHIMIOTHERAPIE: LES NOUVEAUX AGENTS CHIMIOTHERAPIQUES

Référence	population	bras	N pts	RO	SM	p
Mavroudis, 2001 (1)	1^ère ligne, tout stade	CDDP 80 +				NS
		I. VP16 80x3 + PAC 175	62	50%	9,5 m
		II. VP16 120 x 3	71	48%	10,5 m
Noda, 2002 (2)	1^ère ligne, ME	I.CDDP 60 + irinotecan 60 x 3	77	85%	12,8 m	0,002
Noda, 2002 (2)	1^ère ligne, ME	II. CDDP 80 + VP16 100 x 3	77	67%	9,4 m	0,002
Reck, 2003 (3)	1^ère ligne, tout stade	I. Carbo (AUC 5) + VP16 (125) + paclitaxel (175) I.	305	72%	12,7 m	0,024
Reck, 2003 (3)	1^ère ligne, tout stade	II. Carbo (AUC 5) + VP16 (159) + VCR (2)	309	69%	11,7 m	0,024
Seifart, 2005 (4)	1^ère ligne, ME	I. topotecan (1 J1-5) + CDDP (75 J5)	42	61,9%	8,7 m	NS
Seifart, 2005 (4)	1^ère ligne, ME	II. topotecan (1,5 J1-3) + CDDP (75 J3)	42	59,5%	7,6 m	NS
Niell, 2005 (5)	1^ère ligne, ME	CDDP (80 J1) + VP16 (80 J1-3) +				NS
		-	282	65 %	9,9 m
		paclitaxel (175 J1) + GCSF	283	73 %	10,6 m
Quoix, 2005 (6)	1^ère ligne, ME	I. CDDP + topotecan	41	63 %	41,6 s
Quoix, 2005 (6)	1^ère ligne, ME	II. Etoposide + topotecan	41	61 %	43,7 s
Schmitel, 2006 (7)	1^ère ligne, ME	I. Irinotecan + carboplatine	35	67 %
Schmitel, 2006 (7)	1^ère ligne, ME	II. Etoposide + carboplatine	35	59 %
Eckardt, 2006 (8)	1^ère ligne, ME	I. topotecan oral + cisplatine (60)	389	63 %	39,3 s	NS
Eckardt, 2006 (8)	1^ère ligne, ME	II. cisplatin (80) + étoposide	305	69 %	40,3 s	NS
Hanna, 2006 (9)	1^ère ligne, ME	I. irinotecan + cisplatine (30 x 2)	221	48 %	9,3 m	NS
Hanna, 2006 (9)	1^ère ligne, ME	II. cisplatin (60) + étoposide	110	44 %	10,2 m	NS
Socinski, 2006 (10)	1^ère ligne, ME	I. Pemetrexed (500) + cisplatine (75)	40	35 %	7,6 m
Socinski, 2006 (10)	1^ère ligne, ME	II. Pemetrexed (500) + carboplatine (AUC5)	38	39 %	10,4 m
Seifart, 2007 (11)	1^ère ligne, ME	I. topotecan (0.75 J1-5) + carbo (AUC 5 J5)	51	89 %	11,8 m	0,37
Seifart, 2007 (11)	1^ère ligne, ME	I. topotecan (1.25 J1-5) + carbo (AUC 5 J3)	49	80 %	11,6 m	0,37
de Jong, 2007 (12)	1^ère ligne, ME	I. CPA-ADR-VP16	102	60 %	6,8 m	NS
de Jong, 2007 (12)	1^ère ligne, ME	II. Carboplatine + paclitaxel	101	61 %	6,7 m	NS
Sekine, 2008 (13)	1^ère ligne, ME	I. irinotecan + cisplatine	54	76 %	12,4 m	NS
Sekine, 2008 (13)	1^ère ligne, ME	II. Idem + VP16	55	87 %	13,7 m	NS
Hermes, 2008 (14), I	1^ère ligne, ME	I. Irinotecan + Carpoplatine AUC 4	105		8,5 m	0,02
Hermes, 2008 (14), I	1^ère ligne, ME	II. VP16 oral + Carpoblatine AUC 4	104		7,1 m	0,02
Lara, 2009 (15) A	1^ère ligne, ME	I. Cisplatine (60) + irinotecan	324	60 %	9,9 m	NS
Lara, 2009 (15) A	1^ère ligne, ME	II. Cisplatine (80) + étoposide	327	57 %	9,1 m	NS
Socinski, 2009 (16) I	1^ère ligne, ME	I. Carboplatine (AUC 5) + pemetrexed (500)	453	31 %	8,1 m	< 0,01
Socinski, 2009 (16) I	1^ère ligne, ME	II. Carboplatine (AUC 5) + étoposide	455	52 %	10,6 m	< 0,01
Zatloukal, 2010 (17) I	1^ère ligne, ME	I. Cisplatine (80) + irinotecan	202	39 %	10,2 m	0,06
Zatloukal, 2010 (17) I	1^ère ligne, ME	II. Cisplatine (80) + étoposide	203	47 %	9,7 m	0,06
Schmittel, 2011 (18)I	1^ère ligne, ME	I. Carboplatine + irinotécan	106	54 %	10 m	0,06
Schmittel, 2011 (18)I	1^ère ligne, ME	II. Carboplatine + étoposide	110	57 %	9 m	0,06
Fink, 2012 (19) I	1^ère ligne, ME	I. Topotécan + cisplatine	346	55 %	44,9 s	NS
Fink, 2012 (19) I	1^ère ligne, ME	II. Etoposide + cisplatine	334	45 %	40,9 s	NS

Références
(1) Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001 Apr;12(4):463-70.
(2) Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 Jan 10;346(2):85-91.
(3) Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003 Aug 6;95(15):1118-27.
(4) Seifart U, Jensen K, Ukena J, Mueller C, Schroder M, Fuhr HG, et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 2005 Jun;48(3):415-22.
(5) Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005 Jun 1;23(16):3752-9.
(6) Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 2005 Aug;49(2):253-61.
(7) Schmittel A, von Weikersthal LF, Sebastian M, Martus P, Schulze K, Hortig P, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006 Apr;17(4):663-7.
(8) Eckardt JR, von PJ, Papai Z, Tomova A, Tzekova V, Crofts TE, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006 May 1;24(13):2044-51.
(9) Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006 May 1;24(13):2038-43.
(10) Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer 1. J Clin Oncol 2006 Oct 20;24(30):4840-7.
(11) Seifart U, Fink T, Schade-Brittinger C, Hans K, Mueller C, Koschel G, et al. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Ann Oncol 2007 Jan;18(1):104-9.
(12) de Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. Eur J Cancer 2007 Nov;43(16):2345-50.
(13) Sekine I, Nokihara H, Takeda K, Nishiwaki Y, Nakagawa K, Isobe H, et al. Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Br J Cancer 2008 Feb 26;98(4):693-6.
(14) Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008 Sep 10;26(26):4261-7.
(15) Lara PN, Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 May 20;27(15):2530-5.
(16) Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009 Oct 1;27(28):4787-92.
(17) Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010 Sep;21(9):1810-6.
(18) Schmittel A, Sebastian M, Fischer von WL, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011 Aug;22(8):1798-804.
(19) Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial. J Thorac Oncol 2012 Sep;7(9):1432-9.